Search

Your search keyword '"Lerch E"' showing total 113 results
Start Over Author "Lerch E"

Refine your results

more »

more »

more »

more »
113 results on '"Lerch E"'

4. Analysis of traffic conflicts at big intersection types in urban areas

Author

Lerch Elisabeth and Schäfer Petra K.

Subjects
Engineering (General). Civil engineering (General), TA1-2040
Abstract

In the past decades, planners developed intersections for the caroriented city. Above all, they should handle motor vehicle traffic efficiently. Urban areas currently have a high proportion of private cars and, as a result, congestion and high CO2 emissions. At the same time, the importance of and demand for sustainable mobility is increasing. Pedestrians and cyclists are particularly vulnerable as the weakest road users. The goal of transport policy is to achieve “Vision Zero,” i.e., no serious injuries or fatalities in road traffic (Federal Ministry of Digital Affairs and Transport, 2022). Many accidents occur primarily at intersections and junctions. Road traffic authorities in Germany generally use accident data from the accident atlas as the basis for evaluating the road safety of intersections. Planners can improve traffic safety by avoiding critical situations. To this end, an intensive study of the development of conflicts as a precursor to accidents can provide further insights. The research in this project shows that such data on traffic conflicts are not available to road authorities. The project will investigate which and how many conflicts between pedestrian, bicycle, and motor vehicle traffic frequently occur at individual intersection types, such as signalized intersections or traffic circles. The initial goal of the project is to develop a survey concept. In the future, planners should be able to use this to quickly identify risks to pedestrian and bicycle traffic at the types of intersections studied. With the help of vehicle sensor data (e.g. from emergency brake assistants), further findings on the frequency and course of conflicts are to be derived. In addition, a methodology would be developed that will enable traffic planners and municipalities to carry out risk management for intersections in the future in order to improve traffic safety and promote local mobility. From the results of the conflict analysis, we will derive recommendations for transport planning and policy. An action guide will then present the recommendations. The end of the project will be in summer 2024.

Published
2024
Full Text
View/download PDF

6. Power System Technical Performance Issues Related to the Application of Long HVAC Cables

Author

Wiechowski, W., Ohno, T., Emin, Z., Mcdermott, T., Wilson, P., Akhmatov, V., Ametani, A., Bak, C. L., Benato, Roberto, Colla, L., Dorison, E., Dubois, D., Val Escudero, M., Fernandez, F., Golé, A. M., Gudmundsdottir, U. S., Henry, S., de Jong, J., Kessel, J., Lauria, S., Lerch, E., Lesur, F., Marti, L., Palone, F., Popov, M., Faria da Silva, F., de Silva, J., Van der Sluis, L., Sollerkvist, F. J., and Thorburn, S.

Published
2013

7. Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations

Author

Taverna, C., Bargetzi, M., Betticher, D., Gmur, J., Gregor, M., Heim, D., Hess, U., Ketterer, N., Lerch, E., Matthes, Thomas, Mey, U., Pabst, T., and Renner, Christoph

Subjects
ddc:616, Plasma Cells/drug effects/pathology, Dose-Response Relationship, Drug, Biopsy, Needle, Boronic Acids/adverse effects/therapeutic use, ddc:500.2, Antineoplastic Agents/adverse effects/*therapeutic use, Evidence-Based Medicine, Middle Aged, Combined Modality Therapy, Drug Administration Schedule, Multiple Myeloma/diagnosis/*drug therapy/pathology, Bone Marrow/drug effects/pathology, Pyrazines/adverse effects/therapeutic use, Drug Resistance, Neoplasm, Retreatment, Humans, Thalidomide/adverse effects/analogs & derivatives/therapeutic use, Neoplasm Recurrence, Local/drug therapy/pathology, Aged, Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Bone Marrow/drug effects, Bone Marrow/pathology, Bone Marrow Transplantation, Boronic Acids/adverse effects, Boronic Acids/therapeutic use, Multiple Myeloma/diagnosis, Multiple Myeloma/drug therapy, Neoplasm Recurrence, Local/drug therapy, Neoplasm Recurrence, Local/pathology, Plasma Cells/drug effects, Plasma Cells/pathology, Pyrazines/adverse effects, Pyrazines/therapeutic use, Switzerland%22">Type="Geographic">Switzerland, Thalidomide/adverse effects, Thalidomide/analogs & derivatives, Switzerland
Abstract

The treatment of multiple myeloma has undergone significant changes in the recent past. The arrival of novel agents, especially thalidomide, bortezomib and lenalidomide, has expanded treatment options and patient outcomes are improving significantly. This article summarises the discussions of an expert meeting which was held to debate current treatment practices for multiple myeloma in Switzerland concerning the role of the novel agents and to provide recommendations for their use in different treatment stages based on currently available clinical data. Novel agent combinations for the treatment of newly diagnosed, as well as relapsed multiple myeloma are examined. In addition, the role of novel agents in patients with cytogenetic abnormalities and renal impairment, as well as the management of the most frequent side effects of the novel agents are discussed. The aim of this article is to assist in treatment decisions in daily clinical practice to achieve the best possible outcome for patients with multiple myeloma.

Published
2010

48. Long-term protection after stopping venom immunotherapy: Results of re-stings in 200 patients

Author

Lerch, E. and Muller, U.R.

Abstract

Background: Venom immunotherapy (VIT) protects most patients allergic to Hymenoptera stings while booster injections are continued. Few data on long-term protection after discontinuation of treatment are available. Objective: We sought to investigate protection from re-stings over a prolonged period after stopping VIT. Methods: Re-sting data were obtained from 200 of 322 patients in whom VIT had been stopped between 1988 and 1992 after a duration of at least 3 years. The 25 (12.5%) patients who again developed systemic allergic reactions were compared with 50 matched patients without re-sting reactions. Clinical data and diagnostic parameters (i.e., skin sensitivity and specific IgE and IgG) were studied. Results: Of the 25 patients who had re-sting reactions, 19 had been treated with bee venom (relapse rate, 15.8%), and six had been treated with Vespula venom (relapse rate, 7.5%). About half of the re-sting reactions occurred on the first re-sting after stopping VIT. Most of these reactions were mild, whereas the majority of reactions occurring after repeated re-stings were severe. When re-sting reactions were related to the total re-stings per year, an accumulation of sting reactions was observed in years 3 to 5 after stopping VIT. Patients with re-sting reactions had been receiving VIT for a significantly shorter duration (43.35 months) than those with continued protection (54.65 months) (p < 0.01). Of the diagnostic parameters, only a negative intracutaneous skin test at 10^-^3 gm/L predicted long-term protection reliably. Conclusion: Venom immunotherapy of 3 to 5 years duration induces long-term protection in most patients. In rare occasions severe re-sting reactions may, however, occur, especially after repeated re-stings. (J Allergy Clin Immunol 1998;101:606-12.)

Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results